Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study by Regino P. Gonzalez-Peralta, Stefan Wirth, Robert H. Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, Ewa Majda-Stanislawska, Bjorn Fischler, William F. Balistreri, Maureen M. Jonas, Niviann Blondet, Philip Rosenthal, Naim Alkhouri, Rene Romero, Anjana Grandhi, Patricia Castronuovo, Luzelena Caro, Lihong Du, Daniel I.S. Rosenbloom, Barbara A. Haber

Get full text